ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1262

Clinical Features of Elderly-onset Adult Still’s Disease

Sayaka Takenaka1, Takehisa Ogura 1, Yuto Takakura 1, Takaharu Katagiri 1, Yuki Inoue 1, Ayako Hirata 1 and Hideto Kameda 2, 1Division of Rheumatology, Department of Internal medicine Toho University Ohashi Medical Center, Tokyo, Japan, 2Toho University, Tokyo, Japan, Tokyo, Japan

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Adult-onset Still's disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: Miscellaneous Rheumatic & Inflammatory Disease Poster II: Autoinflammation Related Diseases & Therapies

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The peak age at the onset of adult Still’s disease (ASD) has been between 20 and 35 years old. However, the proportion of elderly-onset ASD (EOASD) is increasing in Japan, a country of super-aged society. Therefore, we investigated the clinical features of EOASD in comparison with non-elderly-onset ASD.

Methods: A total of 20 patients with the diagnosis of ASD according to the classification criteria by Yamaguchi et al. between May 2013 and October 2018 in our department were enrolled in this study. Their medical records were intensively reviewed for demographics, clinical manifestations, laboratory data, treatments received and outcome.

Results: Six patients with the age of onset ≥ 65 years (median 71 years old, 5 women) and 14 patients < 65 years (median 38 years old, 12 women). There were no between-group differences in the frequency of fever, sore throat, arthralgia, leukocytosis, liver function abnormality, seronegativity and serum ferritin levels. However, typical rash (50% versus 92%) and lymphadenopathy (50% versus 92%) tended to be less frequently observed in EOASD as compared with non-elderly-onset ASD, and as a result, the number of fulfilled items of Yamaguchi criteria was significantly smaller in EOASD than non-elderly-onset ASD (the median value of 5.5 and 7.5, respectively, p=0.0036). With regard to the treatment, glucocorticoids were administered in 19 patients (initial daily dose of prednisolone 50 mg/day for both groups), and tocilizumab was added in 20% and 35% of EOASD and non-elderly-onset ASD patients respectively. The prognosis was fair except for one patient with non-elderly-onset ASD developing fatal sepsis.

Conclusion: EOASD was not rare (30% of ASD) and showed comparable clinical features and outcomes with non-elderly-onset ASD.


Disclosure: S. Takenaka, None; T. Ogura, None; Y. Takakura, None; T. Katagiri, None; Y. Inoue, None; A. Hirata, None; H. Kameda, AbbVie, 5, 8, Asahi-Kasei Pharma, 5, 8, Astellas, 5, 8, BMS, 5, 8, Chugai Pharmaceutical, 5, 8, Eisai, 5, 8, Eli Lilly and Company, 5, 8, Individual(s) Involved* Select who has the financial relationship., Janssen, 5, 8, Mitsubishi-Tanabe, 5, 8, Novartis, 5, 8, Pfizer, 5, 8.

To cite this abstract in AMA style:

Takenaka S, Ogura T, Takakura Y, Katagiri T, Inoue Y, Hirata A, Kameda H. Clinical Features of Elderly-onset Adult Still’s Disease [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/clinical-features-of-elderly-onset-adult-stills-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-features-of-elderly-onset-adult-stills-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology